Talampanel

Product details

• Chemical name: 1-[(8R)-5-(4-aminophenyl)-8-methyl-8,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone.
• Also known as: Ampanel, Kinampa, LY 300164, GYKI 53773
• CAS number: 161832-65-1
• Molecular formula: C19H19N3O3.
• Purity: >97.8%
• Concentration: 10-300 µM.
• Form: Lyophilized powder.
• Solubility: 100 mM in DMSO. Centrifuge all product preparations before use (10,000 x g for 1 min).
• Reconstitution: 100 mM in DMSO. Centrifuge all product preparations before use (10,000 x g for 1 min).
• Shipping: Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.
• Target: AMPA/Kainate receptors
• Source: Synthetic
• Activity: Talampanel is a potent non-competitive AMPA/kainate receptor antagonist. It potentiates the anticonvulsive activity of antiepileptic drugs in animal models of seizures and is orally active1.
• Alternative names: Ampanel, Kinampa, LY 300164, GYKI 53773

Scientific background

Glutamate is the main excitatory neurotransmitter in the CNS and is also involved in a variety of pathological conditions including epilepsy. Glutamate binds to a number of different receptors such as AMPA, Kainate and NMDA that relay its excitatory activity.Talampanel (Ampanel, Kinampa, LY 300164, GYKI 53773) is a potent non-competitive AMPA and Kainate antagonist. It has an effective concentration of 10-300 µM. Talampanel was examined in several animal models; sub protective doses of Talampanel potentiate the anticonvulsant effect of other anticonvulsant drugs such as valproate and phenytoin. In addition, it shows neuroprotective properties by enabling the survival of hippocampal neurons after carotid artery occlusion. Repeated administrations of Talampanel in rats undergoing middle cerebral artery occlusion (MCAO) caused an improvement in rotarod and beam walking and reduced the number of MCAO induced rotations compared to rats receiving placebo treatment. In humans, Talampanel is administered orally and is well absorbed. It reaches peak concentration after 2 hours with a half-life of 4 hours. In humans, administering valproate with talampanel does not affect talampanel and N-acetyl-talampanel kinetics. Talampanel is used for the treatment of epilepsy and is well tolerated in adults with refractory complex partial seizures. Its main adverse effects are dizziness and ataxia.

Lead time: 1-2 Business Days

Country of origin: Israel/IL

Applications key

Application key: FC- Flow cytometry, IFC- Indirect flow cytometry, IHC- Immunohistochemistry,LCI- Live cell imaging, Calcium imaging assay,Cell survival assay, Electrophysiology, Neurite outgrowth assay.

Bioassay tested: Yes

• SDS (PDF)

Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.

• Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
• Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
• Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
• QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
• Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity

To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).

Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).